POZ Community Forums

Meds, Mind, Body & Benefits => Research News & Studies => Topic started by: Miss Philicia on March 23, 2011, 02:52:21 pm

Title: New Gilead med as effective as Isentress
Post by: Miss Philicia on March 23, 2011, 02:52:21 pm

... further good news on key Gilead component of upcoming "quad" pill

source (http://news.yahoo.com/s/nm/20110323/hl_nm/us_gilead)

Gilead HIV drug as effective as Merck's in trial

Gilead Sciences Inc said on Wednesday that its experimental HIV drug elvitegravir proved as effective as a drug made by Merck & Co in a late-stage clinical trial.

The trial showed that after 48 weeks of treatment, dosed once daily, elvitegravir was as effective as Merck's Isentress, which is dosed twice daily in combination with other antiretroviral drugs.

Gilead's shares rose 2.7 percent to $41.53 in midday trading.

Discontinuation rates caused by adverse events were comparable in both arms of the study, the company said. Gilead plans to submit the data for presentation at a scientific conference later this year.

Elvitegravir is designed to block the ability of the HIV virus to integrate into the genetic material of human cells.

The drug is also part of a four-medicine HIV pill being developed by Gilead known as the "Quad." Last year a mid-stage trial showed the Quad works as well as Gilead's widely used Atripla three-drug tablet.

Atripla combines Emtriva, Viread and Bristol-Myers Squibb Co's Sustiva.

Data from Phase III, or late-stage, Quad trials, which investors are watching closely, are expected beginning in the third quarter of this year.

"We view this as good news for Gilead and believe this data helps de-risk the key Quad Phase IIIs," said Brian Abrahams, an analyst at Wells Fargo, in a research note.

Gilead licensed elvitegravir from Japan Tobacco Inc in March 2005. Gilead has exclusive rights to develop and commercialize the drug everywhere except Japan.

Results of the Phase III elvitegravir trial showed that after 48 weeks of treatment 59 percent of patients taking elvitegravir achieved target reductions in levels of HIV in the blood, known as viral load, compared with 57.8 percent of those who received Isentress, which is also known as raltegravir.

Title: Re: New Gilead med as effective as Isentress
Post by: elf on March 23, 2011, 04:42:53 pm

Thanks for the info.  :-*

Title: Re: New Gilead med as effective as Isentress
Post by: John2038 on October 28, 2011, 01:24:57 pm

Gilead Sciences announced yesterday that it has submitted its investigational once-daily combination “Quad” pill for approval from the United States Food and Drug Administration.

http://www.aidsbeacon.com/news/2011/10/28/gilead-submits-new-drug-application-for-investigational-quad-pill-hiv-aid/

EDIT
Corrected link

Title: Re: New Gilead med as effective as Isentress
Post by: buginme2 on October 28, 2011, 02:26:10 pm

Quote from: John2038 on October 28, 2011, 01:24:57 pm

Gilead Sciences announced yesterday that it has submitted its investigational once-daily combination “Quad” pill for approval from the United States Food and Drug Administration.

http://journals.lww.com/aidsonline/Abstract/publishahead/Fatal_and_non_fatal_AIDS_and_non_AIDS_events_in.99093.aspx

John that link doesnt lead to any information about the quad pill.

Title: Re: New Gilead med as effective as Isentress
Post by: John2038 on October 28, 2011, 02:34:59 pm

Thanks bungime2 & apologies. Corrected

Note

(Reuters) - Gilead Sciences Inc (GILD.O) said its third-quarter net profit rose 5 percent on mixed sales results for its flagship HIV drugs.
http://www.reuters.com/article/2011/10/27/us-gilead-idUSTRE79Q6V820111027

Title: Re: New Gilead med as effective as Isentress
Post by: buginme2 on October 28, 2011, 02:38:15 pm

Thanks I wasnt expecting that until 2012.  

Title: Re: New Gilead med as effective as Isentress
Post by: buginme2 on October 28, 2011, 02:38:57 pm

Quote from: buginme2 on October 28, 2011, 02:38:15 pm

Thanks I wasnt expecting that until 2012.